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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is palbociclib? 
A0022 Who manufactures palbociclib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has palbociclib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 
How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is breast cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of palbociclib on mortality? 
D0005 
How does palbociclib affect symptoms and findings (severity, frequency) of breast 
cancer? 
D0006 How does palbociclib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of palbociclib on patients’ body functions? 
D0012 What is the effect of palbociclib on generic health-related quality of life? 
D0013 What is the effect of palbociclib on disease-specific quality of life? 
Safety 
C0008 How safe is the palbociclib in relation to the comparator(s)? 
C0002 Are there harms related to dosage or frequency of applying palbociclib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of palbociclib? 
A0021 What is the reimbursement status of palbociclib? 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Palbociclib/Ibrance®/PD0332991 
 
B0001: What is palbociclib? 
Cell cycle progression is highly regulated from quiescence (G
0
), pre-DNA 
synthesis (G
1
), DNA synthesis (S), pre-division (G
2
), to mitosis (M). As key 
cell cycle regulators, cyclin-dependent kinases 4 and 6 (CDK4/6) interact 
with cyclin D
1
 to hyperphosphorylate retinoblastoma (Rb), causing the re-
lease of transcription factors that allow cell progression from G1 to S phase. 
Dysregulation of the cell cycle during cancer may occur through loss of Rb 
function, or amplification of cyclin D
1
 or CDK. Palbociclib, a first-in-class, 
reversible, small molecule inhibitor of CDK4/6, blocks Rb phosphorylation 
and prevents cell cycle progression from G
1
 to S phase [2].  
Palbociclib is administered as a 125 mg oral capsule taken once daily for 
three weeks followed by one week off, comprising a 28-day cycle, repeated 
until disease progression. Fulvestrant is co-administered intramuscularly 
(IM) at a dose of 500 mg on days 1, 15, 29, and once every 28 days thereafter. 
Pre- and perimenopausal women are also treated with luteinizing hormone-
releasing hormone (LHRH) agonists such as goserelin according to clinical 
practice [3].  
Complete blood counts (CBC) are monitored prior to starting palbociclib, 
every two weeks for the first two cycles, and monthly thereafter. Dose inter-
ruption, reduction (to 100 mg or 75 mg), or delay in starting a treatment cy-
cle is recommended for patients who develop grade 3 (absolute neutrophil 
count (ANC) 500 - < 1000/mm
3
) or 4 neutropenia (ANC < 5000/mm
3
), or 
grade ≥ 3 non-hematologic toxicity. Patients should avoid concomitant use 
of strong CYP3A inhibitors or have their dose reduced to 75 mg once daily. 
If a dose reduction below 75 mg/day is required treatment should be discon-
tinued [3]. 
 
A0022: Who manufactures palbociclib? 
Pfizer Inc. 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Palbociclib is indicated as treatment for hormone receptor (HR)-positive, 
human epidermal growth factor receptor 2 (HER2)-negative advanced or 
metastatic breast cancer (MBC) in combination with fulvestrant in women 
with disease progression during or following endocrine therapy (ET) [3].  
first-in-class 
CDK4/6 inhibitor 
125 mg/day for 3 weeks, 
1 week off 
monitor CBC, 
reduce/interrupt dose 
for safety/tolerability 
HR-positive, HER2-
negative advanced or 
MBC 
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4 Current regulatory status 
A0020: For which indications has palbociclib received marketing authorisa-
tion? 
In February 2015, the US Food and Drug Administration (FDA) granted ac-
celerated approval of palbociclib for the treatment of postmenopausal wom-
en with HR-positive, HER2-negative advanced breast cancer as first-line 
treatment in combination with letrozole. Initial approval was based on the 
results of a phase II study (PALOMA-1) and confirmed in a phase III study 
(PALOMA-2) [4].  
In February 2016, the FDA expanded the licensing indication to include 
palbociclib in combination with fulvestrant for women with HR-positive, 
HER2-negative advanced or MBC with disease progression during or follow-
ing ET. Expanded approval was based on the results of the phase III 
PALOMA-3 trial [5]. 
Palbociclib has received marketing authorisation by the European Medi-
cines Agency (EMA) in November 2016 for the treatment of HR-positive, 
HER2-negative locally advanced breast cancer (LABC) or MBC in combina-
tion with an aromatase inhibitor (AI), or in combination with fulvestrant in 
women who have received prior ET [6].  
 
 
5 Burden of disease 
A0002: What is breast cancer? 
Breast cancer commonly develops from an uncontrolled growth of epithelial 
cells lining the milk ducts and/or lobules caused by dysregulation of the cell 
cycle. In the early stages, atypical cells confined to the milk ducts are termed 
stage 0, ductal carcinoma in situ (DCIS). Stage I breast cancer is invasive, 
but is restricted to the area where the first abnormal cells arose. Most (70%–
80% of) breast cancers are diagnosed as stage I (localized to one area) or 
stage II (early locally advanced), invasive ductal carcinoma (IDC) or inva-
sive lobular carcinoma (ILC), where abnormal cells have spread beyond the 
ducts or glands into breast tissue.  
Stage III, LABC includes tumours larger than 5 cm in diameter that involve 
the skin, underlying muscle, lymph nodes or inflammatory breast cancer 
(IBC). All primary invasive cancers are evaluated for HR status and HER2 
expression. HR-positive cancers account for approximately 65% and 80% of 
breast cancers in pre- and postmenopausal women, respectively [7]. HER2 is 
overexpressed in approximately 15%–23% of patients [7]. HR-positive, 
HER2-negative is the most common type of breast cancer, accounting for 
approximately 70% of cases. Between 5% and 10% of patients are diagnosed 
with stage IV MBC that has spread beyond the breast and lymph nodes [7-
FDA: licensed as 1st-line 
with letrozole in 
February 2015 
FDA: licensed as 2nd-line 
with fulvestrant in 
February 2016 
EMA: marketing 
authorisation for 
LABC/MBC in November 
2016 
HR-positive, HER2-
negative is the most 
common type of breast 
cancer 
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9]. MBC that can no longer be controlled is considered advanced or pallia-
tive [10].  
 
A0004: What is the natural course of breast cancer? 
Breast cancer cells commonly travel through the lymphatic system and 
blood stream forming metastatic tumours in bone, liver, lungs and brain. 
Stage IV breast cancers that have spread to distant parts of the body have a 
poor prognosis with five-year survival rates of less than 25% [7].  
 
A0006: What are the consequences of breast cancer for the society? 
Globally, breast cancer is the most frequently diagnosed malignancy and the 
leading cause of cancer death in women worldwide [9]. Approximately 30% 
of women diagnosed with early stage breast cancer develop advanced or 
MBC despite treatment [7]. Patients may progress or further metastasize, 
causing significant cancer specific morbidity and mortality. In Austria, 
breast cancer is the 19
th
 leading cause of disability adjusted life years and ac-
counts for approximately 28,000 (2.6% of total) years of life lost due to 
premature mortality [11].  
 
A0023: How many people belong to the target population? 
In Austria, 5,521 new cases of breast cancer were diagnosed in 2012, with a 
corresponding incidence rate of 40.3 per 1,000,000 persons; 1.1 per 100,000 
men and 76.1 per 100,000 women (based on the WHO-world population 
2011). Accounting for 30% of all cancers, breast cancer is the most frequent-
ly diagnosed cancer among Austrian women and the leading cause of death 
due to cancer. Breast cancer attributed to 1,548 deaths with an overall mor-
tality of 8.9 per 100,000 persons; 0.3 per 100,000 men and 16.0 per 100,000 
women (based on the WHO-world population 2011) [12].  
 
A0005: What are the symptoms and the burden of breast cancer? 
Signs of breast cancer may include a hard, immovable, lump in the breast 
with irregular borders. Patients with LABC may experience dimpling or 
thickening of the skin, a change in shape or colour, nipple inversion or dis-
charge, and pain in the breast or armpit. Patients with MBC may experience 
bone pain, fractures, headaches, seizures, swollen lymph nodes, shortness of 
breath or jaundice depending on the organs involved [10, 13].  
 
A0003: What are the known risk factors for breast cancer? 
Risk factors for developing breast cancer include increasing age, female 
gender, a personal or family history of breast cancer, Caucasian race, obesi-
ty, early menarche, nulliparity or older age at first birth, late menopause, 
hormone replacement therapy, increased breast density, alcohol consump-
tion and cigarette smoking [10]. According to data from the Surveillance Ep-
idemiology, and End Results (SEER) database, the probability of developing 
breast cancer in the United States between 2006 and 2008 was 2.3 (1 in 44 
women) for women aged 50 to 59 years of age, 3.5 (1 in 29 women) for those 
metastasize to bone, 
liver, lungs, brain; 5 
years survival < 25% 
metastasize; leading 
cause of cancer death in 
women worldwide 
5,521 new cases of breast 
cancer in Austria in 
2012, 1,548 deaths 
main symptoms: breast 
lump, thickening, pain 
main risk factors: 
increasing age, female 
gender, Caucasian race 
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aged 60 to 69 years, and 6.7 (1 in 15 women) for women above the age of 70 
years [9, 10]. 
 
A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
A mammogram of both breasts is performed to define tumour size and assess 
whether the contralateral breast is affected. Breast magnetic resonance imag-
ing (MRI) or ultrasound may also be performed to estimate tumour size and 
distinguish a fluid-filled or a solid mass. During a biopsy, a sample of breast 
cells or tissue from the lump is examined to determine the presence of can-
cer cells, and HR or HER2 protein expression. HR status is an important 
factor in planning clinical management. Bone scans, blood tests, x-rays, CT 
and PET scans may be conducted to determine whether breast cancer has 
spread to bone, liver, lungs or brain [9, 14]. 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
Previously untreated, advanced and MBC that is HR-positive and HER2-
negative is treated using ET and/or chemotherapy and/or surgery and/or ra-
diation therapy and/or targeted therapy.  
First-line ET involves: 
 a third generation aromatase inhibitor (AI) (anastrozole, letrozole, 
or exemestane) for postmenopausal patients;  
 tamoxifen and ovarian suppression with LHRH agonists or tamoxi-
fen alone for premenopausal patients; and 
Patients who progress on ET may undergo second-line treatment involving:  
 a non-cross-resistant AI, tamoxifen, the selective estrogen down-
regulator (SERD) fulvestrant, fulvestrant plus an AI, an AI plus a 
CDK 4/6 inhibitor, any ET in combination with the rapamycin in-
hibitor everolimus [8, 15, 16]. 
 
If advanced or MBC can no longer be controlled, treatment to slow tumour 
growth or palliative care to manage cancer symptoms and side effects of 
therapies can be applied[10].  
 
 
7 Evidence 
A literature search was conducted on 25 October 2016 in five databases: 
the Cochrane Library, CRD Database, Embase, Ovid Medline and Pub-
Med. Search terms included “Palbociclib”, “PD-0332991”, “breast cancer” 
diagnostics: 
mammography, biopsy, 
HR status, bone, CT, PET 
scans 
1st-line: ET involving 
tamoxifen with LHRH 
agonists; AIs +/- CDK 
inhibitor 
2nd-line: fulvestrant or 
exemestane with 
everolimus 
advanced: continue 
treatment or undergo 
palliative care 
278 citations; phase III 
RCT, PALOMA-3  
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and “breast neoplasms”. The manufacturer was also contacted and submit-
ted five studies, all of which were identified through the literature search. 
Manual searching yielded an FDA approval document [3], EMA initial au-
thorisation [6], two clinical guidance documents [9, 15], two clinical study 
reports [17, 18], an economic guidance report [19], a press release [20], and 
statistical information [12].  
Overall, 278 citations were identified; a multicentre, randomized, phase III 
trial (PALOMA-3) contributed to the evidence regarding the efficacy and 
safety of palbociclib in combination with fulvestrant for the treatment of 
HR-positive, HER2-negative MBC [21-25].  
The methodological quality of the evidence was conducted to assess the risk 
of bias at the study level based on EUnetHTA internal validity for RCTs 
[26]. Evidence was assessed based on adequate generation of randomisation 
sequence, allocation concealment, blinding of patient and treating physi-
cian, selective outcome reporting and other aspects that may increase the 
risk of bias. Details of study quality are reported in Table 5 of the appendix.  
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [27]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [28]. Details of the magnitude 
of clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety –  
Phase III studies 
PALOMA-3, a global multicentre, randomised, double-blind, placebo-
controlled, phase III study assessed the safety and efficacy of palbociclib in 
combination with fulvestrant as second-line treatment for HR-positive, 
HER2-negative advanced or MBC in women with disease progression during 
or following ET. Eligible patients were 18 years and older, with confirmed 
HR-positive, HER2-negative MBC, Eastern Co-operative Oncology Group 
(ECOG) performance status 0–1, bone disease or measurable disease defined 
by Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 
v1.1), with relapse or progression following previous ET. Patients that re-
ceived one prior line of chemotherapy for advanced disease were also eligible 
for study. Pre- and perimenopausal women received LHRH agonist treat-
ment with goserelin 4 weeks prior to randomisation. Patients previously 
treated with fulvestrant, everolimus or a CDK or PI3K/mTOR inhibitor; 
and those with extensive metastasis were excluded [21].  
Patients were stratified by sensitivity to ET, menopausal status, and pres-
ence of visceral metastasis. A centralised interactive system block random-
ised 521 women to receive palbociclib plus fulvestrant (n = 347) or placebo 
plus fulvestrant (n = 174) in a 2:1 ratio. Fulvestrant 500 mg was adminis-
tered by intramuscular (IM) injection on days 1, 15, 29, and once every 28 
days thereafter. Patients received 125 mg oral palbociclib or matching pla-
cebo once daily for 3 weeks, followed by a week off, comprising a 28-day cy-
cle that repeated until disease progression or unacceptable toxicity. A dose 
modification strategy was adopted for patients who experienced investiga-
tional drug toxicity. The primary endpoint was investigator-assessed PFS 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
PALOMA-3: efficacy and 
safety of palbociclib + 
fulvestrant (n=521) 
primary endpoint: 
investigator-assessed 
PFS; secondary 
endpoints: OS, ORR, 
DOR, PROs 
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defined as the time from randomisation to radiological disease progression 
or death. Secondary endpoints included overall survival (OS), confirmed ob-
jective response rate (ORR), duration of response (DOR); patient-reported 
outcomes (PROs) and safety [23, 25]. The mutation statuses of PIK3CA, and 
the estrogen receptor gene ESR1 were assessed at baseline [21, 24].  
Interim analysis at a cut-off of 195 PFS events on Dec 5, 2014 resulted in 
stopping the trial early in April 2015, because significant efficacy was 
reached having crossed the pre-specified Haybittle-Peto efficacy-stopping 
boundary ( = 0.00135). Later statistical analyses at a cut-off of 259 PFS 
events on March 16, 2015 supported the results of the interim analysis. Me-
dian follow-up was 8.9 months (IQR 8.7–9.2); 191 (55% of) patients receiving 
palbociclib plus fulvestrant and 51 (29% of) placebo plus fulvestrant pa-
tients remained on treatment [21]. Approximately 128 (37% of 347) patients 
discontinued treatment due to disease progression in the palbociclib plus 
fulvestrant group compared to 107 (61% of 174) patients in the placebo plus 
fulvestrant group.  
Patients had a median age of 57 years, 74% were Caucasian, 80% were post-
menopausal, and all had an ECOG PS of 0–1 and prior systemic therapy; 
75% had received prior chemotherapy. Approximately 25% of patients had 
received no prior therapy in the metastatic setting, 60% had visceral metas-
tases, and 23% had bone disease [3]. PIK3CA mutations were detected in 
129 (33% of 395) of available samples and baseline demographics and clini-
cal characteristics did not differ by PIK3CA status [3]. ESR1 mutations were 
found in 25% (91 of 360) of patients, of whom 29% (26 of 91) had mutations 
conferring acquired resistance to prior AI [24]. Detailed patient characteris-
tics, including inclusion and exclusion criteria, are reported in Table 4 of 
the appendix.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of palbociclib on mortality? 
At the time of final analysis of PFS, OS data were not mature with only 29% 
of events. By the time of analysis, 57 deaths had occurred in the palbociclib 
plus fulvestrant group and 21 occurred in the placebo plus fulvestrant 
group, accounting for only 29% of the 197 events needed for an OS analysis 
[21]. The efficacy of palbociclib is reported in Table 1.  
 
D0006: How does palbociclib affect progression (or recurrence) of advanced 
or MBC? 
Median PFS was 9.5 months (95% CI 9.2–11.0) in the palbociclib plus ful-
vestrant group compared with 4.6 months (95% CI 3.5–5.6) in the placebo 
plus fulvestrant group (HR 0.46, 95% CI 0.36–0.59; two-sided p < 0.0001) in 
the intention to treat analysis [21]. Response to treatment was not signifi-
cantly affected by the PIK3A status or the level of expression of HR [21]. 
Palbociclib plus fulvestrant significantly improved PFS compared to place-
bo plus fulvestrant in both patients with ESR1 mutations (HR 0.43, 95% CI 
0.25–0.74; p = 0.0021) and those without (HR 0.48, 95% CI 0.35–0.70; p < 
0.001) [24]. Palbociclib plus fulvestrant resulted in longer PFS than fulves-
trant alone [21, 22]. 
 
trial stopped early due 
to significant efficacy 
results 
median age of 57 years, 
randomisation stratified 
by ET sensitivity, 
menopausal status, and 
visceral metastasis 
OS: not mature; only 
29% of 197 events had 
occurred by the time of 
final analysis of PFS 
palbociclib extended 
median PFS from 4.6 
months to 9.5 months  
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D0005: How does palbociclib affect symptoms and findings (severity, fre-
quency) of advanced and MBC? 
Of patients with measurable disease at baseline, 66 (24.6%, 95% CI 
19.6-30.2) in the palbociclib plus fulvestrant group showed an objective re-
sponse versus 15 (10.9%, 95% CI 6.2–17.3) in the placebo plus fulvestrant 
group (OR 2.69, 95% CI 1.43–5.26; two-sided p = 0.0012) [21]. Significantly 
greater improvement from baseline in pain was also observed (-3.3 [95% CI -
5.1 – -1.5] versus 2.0 [95% CI -0.6–4.6; p = 0.0011]) [23]. Duration of re-
sponse was 9.3 months in the palbociclib plus fulvestrant group compared 
with 7.6 months in the placebo plus fulvestrant group [3]. The median time 
to response was 112 days (IQR 58–160) for the palbociclib plus fulvestrant 
group and 57 days (52–106) for the placebo plus fulvestrant group [21]. The 
efficacy of palbociclib plus fulvestrant and the probability of disease pro-
gression after 6 months were not significantly associated with the level of 
HR expression [21].  
 
D0011: What is the effect of palbociclib on patients’ body functions? 
Palbociclib undergoes hepatic metabolism by CYP3A and SULT2A1 en-
zymes. Mild or moderate hepatic or renal impairment did not affect the safe-
ty or efficacy of palbociclib according to a pharmacokinetic analysis involv-
ing 183 patients [3].  
 
D0012: What is the effect of palbociclib on generic health-related quality of 
life? 
Results of the global QoL scale using the European Organisation for Re-
search and Treatment of Cancer Quality-of-Life Questionnaire (EORTC 
QLQ-C30) were in favour of palbociclib, with estimated QoL scores 66.1 
(95% CI 64.5–67.7) versus 63.0 (95% CI 60.6–65.3; p = 0.0313) [23]. The 
overall change from baseline was -0.9 (95% CI -2.5–0.7) in the palbociclib 
plus fulvestrant group and -4.0 (95% CI -6.3–1.7) in the placebo plus fulves-
trant group [23]. From the five functional scales of the EORTC QLQ-C30, 
only the emotional functioning scale differed, also favouring palbociclib 
[29]. Treatment with palbociclib plus fulvestrant significantly delayed dete-
rioration in global QoL (p < 0.025) and pain (p < 0.001) compared to place-
bo and fulvestrant. Palbociclib plus fulvestrant allowed patients to maintain 
their QoL [23]. 
 
D0013: What is the effect of palbociclib on disease-specific quality of life? 
Results of the European Organisation for Research and Treatment of Cancer 
Quality-of-Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23) 
suggest favour towards placebo regarding being upset about the loss of one’s 
hair. There was an improvement in the median time to deterioration in pain 
from 3.5 months (95% CI 2.5–5.4) in the placebo plus fulvestrant group to 
7.2 months in the palbociclib plus fulvestrant group (95% CI 5.6–NE; 
HR 0.66, 95% CI 0.51–0.88).  
 
 
significant improvement 
in ORR, and pain 
compared to placebo; 
DOR was 9.3 months 
mild/ moderate hepatic 
impairment: 
no effects on efficacy  
difference on QoL scale: 
66.1 vs. 63.0 in favour of 
palbociclib 
 
 
delayed deterioration  
in QoL 
delayed deterioration  
in pain 
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Table 1: Efficacy results of the phase III PALOMA-3 phase trial [3, 21, 23] 
Descriptive statistics and 
estimate variability (da-
ta cut-off of March 16, 
2016) 
Treatment group Palbociclib + fulvestrant Placebo + fulvestrant 
Number of subjects n = 347 n = 174 
Median PFS, months 9.5 (95% CI 9.2–11.0) 4.6 (95% CI 3.5–5.6) 
Number of PFS 
events, n (%) 
145 (41.8) 114 (65) 
OS NR NR 
ORR, n (%) of pa-
tients 
66 
(24.6%, 95% CI 19.6–30.2) 
15 
(10.9%, 95% CI 6.2–17.3) 
DOR, months [3] 9.3 7.6 
PROs[23, 29] 
Overall global QoL 
EORTC QLQ-C30 
(pain) 
  EORTC QLQ-C301 
  EORTC QLQ-BR232 
 
66.1 (95% CI 64.5–67.7) 
 
-3.3 (CI -5.1 – -1.5) 
-0.9 (95% CI -2.5–0.7) 
3.5 (95% CI 2.5–5.4) 
 
63.0 (95% CI 60.6–65.3) 
 
2.0 (95% CI -0.6–4.6)  
-4.0 (95% CI -6.3–1.7) 
7.2 (95% CI 5.6, NE) 
Effect estimate  
per comparison 
Comparison groups Palbociclib + fulvestrant versus 
Placebo + fulvestrant 
 Median PFS, months HR 0.46 
95% CI 0.36–0.59 
Two-sided log-rank p < 0.0001 
Number of PFS events HR 0.46 
95% CI 0.36–0.59 
Two-sided log-rank p < 0.0001 
OS NR NR 
ORR, n (%) of pa-
tients 
 
OR 2.69 
95% CI 1.43–5.26 
Two-sided log-rank p = 0.0012 
DOR NR NR 
PROs[23, 29] 
   EORTC QLQ-BR23 
HR 0.66 
95% 0.51–0.88 
NR NR 
Notes NSD in PFS between patients with (n = 129) and without (n = 266) PIK3CA mutations. Medi-
an PFS was 5.8 months (95% CI 5.3–9.5) in patients with PIK3CA mutations and 9.2 months 
(95% CI 7.5–10.8) in patients without mutations (HR 1.26, 95% CI 0.94–1.68; one-sided log-
rank p = 0.94). In patients with a PIK3CA mutation, median PFS was 9.5 months (95% CI 4.7–
11.2) in palbociclib plus fulvestrant group and 3.6 months (95% CI 1.9–5.6) in the placebo plus 
fulvestrant group (HR 0.48, 95% CI 0.30–0.78; two-sided log-rank p = 0.002). NSD in the 
magnitude of benefit associated with palbociclib plus fulvestrant (two-sided pintervention = 0.83) 
or HR status (0.77). At the time of final analysis of PFS, OS data were not mature with 29% 
of events.  
Abbreviations: CI = confidence interval; DOR = duration of response; EORTC QLQ-C30 = European Organisation for Research and 
treatment of Cancer Quality-of-Life Questionnaire; EORTIC QLQ-BR23 = European Organisation for Research and treatment of Cancer 
Quality-of-Life Questionnaire Breast Cancer Module; HR = hazard ratio; OR: odds ratio; NE = not estimable; NR = not reported; NSD 
= no significant difference; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PROs = patient 
reported outcomes 
 
 
                                                             
1
 global QoL scale (EORTC QLQ-C30)  overall change from baseline 
2
 median time to deterioration in pain (EORTC QLQ-BR23) 
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7.1.2 Safety 
C0008: How safe is palbociclib in relation to the comparator(s)? 
Serious adverse events (SAEs) occurred in 44 (13%) of 345 palbociclib plus 
fulvestrant recipients and 30 (17%) of 172 placebo plus fulvestrant 
recipients [21]. Neutropenia, of all grades, was substantially more frequent 
in the palbociclib plus fulvestrant group than in the placebo plus fulvestrant 
group (286 [83%] of 345 palbociclib recipients versus 7 [4%] of 172 placebo 
recipients) [3]. Grade 3 or 4 neutropenia was reported in 228 (66%) of 345 
patients receiving palbociclib plus fulvestrant and 2 (1%) patients receiving 
placebo plus fulvestrant [3]. The median time to first episode of neutropenia 
was 15 days; the median duration of grade 3 neutropenia was 7 days [3, 25]. 
Palbociclib plus fulvestrant resulted in one death due to neutropenic sepsis 
[3].  
Leukopenia, of all grades, was also significantly more common in the palbo-
ciclib plus fulvestrant group than in the placebo plus fulvestrant group (183 
[53%] of 345 versus 9 [5%] of 172) [3]. Grade 3 or 4 leukopenia was reported 
in 108 (31%) of 345 palbociclib recipients versus 4 (2%) of patients receiving 
placebo [3]. Pulmonary embolism was reported at a higher rate in palbo-
ciclib plus fulvestrant- treated patients (1%) compared with no cases in 
those treated with placebo plus fulvestrant [3]. Anaemia was reported in 104 
(30%) of palbociclib plus fulvestrant recipients versus 22 (13%) of patients 
receiving placebo [3]. 
The most common adverse events (AEs) occurring in 10% of palbociclib 
plus fulvestrant recipients were neutropenia, leukopenia, infections, fatigue, 
nausea, anaemia, stomatitis, headache, diarrhoea, thrombocytopenia, con-
stipation, vomiting, alopecia, rash, decreased appetite, and pyrexia, Table 2 
[3, 29].  
 
C0002: Are there harms related to dosage or frequency of applying 
palbociclib? 
Investigators reported that palbociclib plus fulvestrant was well tolerated; 
neutropenia was effectively managed by dose modification without loss of ef-
ficacy [25]. In the palbociclib plus fulvestrant group, 187 (54%) patients 
experienced a dose interrruption due to an AE, 123 (36%) patients had a 
cycle delay, and 117 (34%) patients had at least one dose reduction during 
the study compared to 10 (6%), three (2%), and three (2%), respectively, in 
the placebo plus fulvestrant group [21]. AEs accounted for permanent 
discontinued treatment in 19 (6% of 345) palbociclib plus fulvestrant 
recipients and six (3% of 172) placebo plus fulvestrant recipients [3]. AEs 
causing discontinuation in palbociclib plus fulvestrant recipients included 
fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of palbociclib? 
Palbociclib is not recommended for use in pregnant or lactating women due 
to potential risk of miscarriage, birth defects and AEs in infants. Women are 
advised to use effective contraception during treatment and at least 3 weeks 
following the last dose. Concomitant use of strong CYP3A inhibitors or in-
ducers should be avoided [3].  
SAE: I 13 % vs. C 17% 
 
Neutropenia: 
I 83% vs. C 4% 
Neutropenia grade 3: 
I 66% vs. 1% 
 
Leukopenia: 
I 53% vs C 5% 
most common AEs: 
neutropenia, 
leukopenia, infection, 
fatigue, nausea, 
anaemia, stomatitis, 
headache, diarrhoea, 
thrombocytopenia, 
constipation, vomiting, 
alopecia, rash, decreased 
appetite, pyrexia 
 
54% of patients  
dose interruption  
 
36% cycle delay 
34% dose reduction  
 
6% discontinued  
due to AE 
 
pregnant or  
lactating women 
 concomitant CYP3A 
inhibitors or inducers 
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Table 2: Most frequent adverse events [3] 
 
Adverse Event (according  
to CTCAE C version4.0) 
 
Palbociclib + fulvestrant  
(n = 345) 
 
Placebo + fulvestrant  
(n = 172) 
 All Grades 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
All Grades 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Infections 162 (47) 10 (3) 4 (1) 53 (31) 5 (3) 0 (0%) 
Blood and lymph disorders 
   Febrile neutropenia 
   Neutropenia 
   Leukopenia 
   Anaemia 
   Thrombocytopenia 
 
4 (1) 
286 (83) 
183 (53) 
104 (30) 
79 (23) 
 
4 (1) 
190 (55) 
104 (30) 
10 (3) 
7 (2) 
 
0 (0) 
38 (11) 
4 (1) 
0 (0) 
4 (1) 
 
2 (1) 
7 (4) 
9 (5) 
22 (13) 
0 (0) 
 
0 (0) 
2 (1) 
2 (1) 
7 (2) 
0 (0) 
 
2 (1) 
0 (0) 
2 (1) 
0 (0) 
0 (0) 
Decreased appetite 55 (16) 4 (1) 0 (0) 14 (8) 2 (1) 0 (0) 
Headache 90 (26) 4 (1) 0 (0) 34 (20) 0 (0) 0 (0) 
Gastrointestinal disorders 
   Nausea 
   Stomatitis 
   Diarrhoea 
   Constipation 
   Vomiting 
 
117 (34) 
97 (28) 
83 (24) 
69 (20) 
66 (19) 
 
0 (0) 
4 (1) 
0 (0) 
0 (0) 
4 (1) 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
48 (28) 
22 (13) 
33 (19) 
28 (16) 
26 (15) 
 
2 (1) 
0 (0) 
2 (1) 
0 (0) 
2 (1) 
 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Skin disorders 
   Alopecia 
   Rash 
 
62 (18) 
59 (17) 
 
N/A 
4 (1) 
 
N/A 
0 (0) 
 
10 (6) 
10 (6) 
 
N/A 
0 (0) 
 
N/A 
0 (0) 
General disorders 
   Fatigue 
   Asthenia 
   Pyrexia 
 
141 (41) 
28 (8) 
49 (13) 
 
7 (2) 
0 (0) 
1 (<1) 
 
0 (0) 
0 (0) 
0 (0) 
 
50 (29) 
9 (5) 
9 (5) 
 
2 (1) 
2 (1) 
0 (0) 
 
0 (0) 
0 (0) 
0 (0) 
Laboratory abnormalities 
   WBC decreased 
   Neutrophils decreased 
   Anaemia 
   Platelets decreased 
 
342 (99) 
331 (96) 
269 (78) 
214 (62) 
 
155 (45) 
193 (56) 
10 (3) 
7 (2) 
 
4 (1) 
38 (11) 
0 (0) 
4 (1) 
 
45 (26) 
24 (14) 
69 (40) 
17 (10) 
 
0 (0) 
0 (0) 
7 (2) 
0 (0) 
 
2 (1) 
2 (1) 
0 (0) 
0 (0) 
Abbreviations: CTCAE = common terminology criteria for adverse events 
 
7.2 Clinical effectiveness and safety – further studies 
The US FDA granted accelerated approval of palbociclib in combination 
with letrozole as first-line treatment for postmenopausal women with HR-
positive, HER2-negative MBC based on results of the phase II PALOMA-1 
trial (TRIO-18; Study 1003; A5481003; and NCT00721409) [30]. Patients 
were randomised to receive letrozole alone or in combination with palbo-
ciclib 125 mg daily for three weeks followed by one week off. Palbociclib 
plus letrozole increased median PFS from 10.2 months to 20.2 months com-
pared to letrozole alone (HR 0.488; 95% CI 0.319–0.748; one-sided 
p = 0.0004). Palbociclib increased the median DOR from 7.6 months to 13.8 
months.  
Dose reduction due to an AE occurred in 36% of palbociclib plus letrozole 
recipients, while no reductions were observed in letrozole-treated patients. 
Approximately 8% of palbociclib plus letrozole recipients permanently dis-
PALOMA-1: Phase II 
palbociclib + letrozole  
 
increased median PFS 
10.2 months to 20.2 
months compared to 
letrozole-alone 
dose reductions:  
36% of patients 
discontinuation: 8% 
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continued treatment due to neutropenia, asthenia and fatigue. The most 
common AEs occurring in  10% of patients, included neutropenia, leuko-
penia, fatigue, anaemia, infections, nausea, stomatitis, alopecia, diarrhoea, 
thrombocytopenia, decreased appetite, vomiting, asthenia, peripheral neu-
ropathy, and epistaxis. SAEs reported in palbociclib plus letrozole treated 
patients included pulmonary embolism (3 of 83, 4%) and diarrhoea (2 of 83, 
2%) [3]. The study was limited in that it was of open-label design, had insuf-
ficient power to detect OS, the endpoint was investigator assessed with lack 
of central radiology review, and modifications were made to the statistical 
analysis that could increase type 1 error [2].  
The safety and efficacy of palbociclib plus letrozole as first-line treatment 
for HR-positive, HER-2-negative advanced breast cancer was confirmed in a 
multicentre, double-blind, phase III study, PALOMA-2 [4] involving 666 pa-
tients. Postmenopausal patients were randomly assigned to receive 125 mg 
of palbociclib per day, or matching placebo for three weeks followed by one 
week off. All patients received 2.5 mg of letrozole per day. Palbociclib plus 
letrozole increased the median PFS from 14.5 months to 24.8 months (HR 
0.58; 95% CI, 0.46–0.72; p < 0.001). The most common grade 3 or 4 AEs 
were neutropenia, leukopenia, anaemia and fatigue. AEs resulting in discon-
tinuation of treatment occurred in 43 (9.7%) palbociclib plus letrozole pa-
tients and in 13 (5.9%) of placebo plus letrozole recipients. The study was 
limited due to immature OS data at the time of analysis. An OS analysis will 
be conducted when a total number of 390 death have occurred per protocol 
[4]. 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of the technology? 
Palbociclib is available as 75, 100, and 125 mg capsules. At the recommend-
ed dose of 125 mg once daily for three weeks, followed by one week off, pal-
bociclib costs approximately € 4,582.55 per 28-day cycle [31]. Additional 
costs will incur due to the combination of palbociclib with fulvestrant.  
 
 
9 Ongoing research 
In November 2016, a search in databases http://clinicaltrials.gov/ and 
https://www.clinicaltrialsregister.eu/ctr-search/ was conducted. The follow-
ing ongoing phase III trials are investigating palbociclib in HR-positive 
MBC: 
 NCT02028507: Phase III study of palbociclib (PD-0332991) in 
combination with ET (exemestane or fulvestrant) versus chemo-
therapy (capecitabine) in HR- positive, HER2-negative MBC pa-
tients with resistance to non-steroidal AIs. Estimated study comple-
tion date is July 2020. 
palbociclib 
monotherapy as 3rd line 
for Rb-positive MBC: 
benefit in 19% 
€ 4,582.55 per 28-day 
cycle 
5 phase III studies are 
ongoing, investigating 
palbociclib in MBC 
patients 
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®
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 NCT02297438: A multicentre, randomized, double-blind phase III 
study Of palbociclib (oral Cdk 4/6 inhibitor) plus letrozole versus 
placebo plus letrozole for the treatment of previously untreated 
Asian postmenopausal women with HR-positive, HER2-negative 
advanced breast cancer. Estimated study completion date is April 
2018. 
 NCT02513394: Palbociclib collaborative adjuvant study: a random-
ized phase III trial of palbociclib with standard adjuvant ET Versus 
Standard adjuvant ET alone for HR-positive, HER2-negative early 
breast cancer. Estimated study completion date is September 2025. 
 NCT01864746: Phase III study evaluating palbociclib (PD-
0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in pa-
tients with HR-positive, HER2-normal primary breast cancer with 
high relapse risk after neoadjuvant chemotherapy "PENELOPE-B". 
Estimated study completion date is November 2023. 
 NCT02600923: Phase III, open label study of palbociclib in combi-
nation with letrozole as treatment for postmenopausal women with 
HR-positive, HER2-negative advanced breast cancer for whom let-
rozole is deemed appropriate. Estimated study completion date is 
October 2018.  
Various phase I and II trials are currently ongoing that are investigating 
palbociclib in different treatment regimens and combinations in HR-
positive MBC (NCT02592746, NCT02668666, NCT02599714, 
NCT02448420, NCT02605486, NCT02491983, NCT02592083, 
NCT02549430). 
 
 
10 Discussion 
In February 2015, the US FDA issued a first-in-class, accelerated approval 
for the CDK4/6 inhibitor palbociclib, plus letrozole, as first-line treatment 
for postmenopausal women with HR-positive, HER2-negative advanced 
breast cancer. Initial approval was based on the phase II PALOMA-1 trial 
demonstrating palbociclib plus letrozole increased median PFS by 10 
months compared to letrozole alone. The safety and efficacy was confirmed 
in a phase III trial (PALOMA-2) [4]. In February 2016, licensing was ex-
panded to include palbociclib plus fulvestrant, for women with HR-positive, 
HER2-negative advanced or MBC with disease progression during or follow-
ing ET. Expanded approval was based the phase III PALOMA-3 trial show-
ing palbociclib plus fulvestrant increased median PFS by 4.9 months com-
pared to palbociclib plus placebo [3, 29]. In November 2016, palbociclib was 
approved by the EMA for treatment of HR-positive, HER2-negative ad-
vanced or MBC in combination with an aromatase inhibitor (AI) or with 
fulvestrant in women who progress during or following ET [6]. 
various ongoing phase I 
and II trials for the 
treatment of HR-
positive MBC 
marketing authorisation 
in the US since February 
2015 
 
 
 
indication approved by 
the FDA in 2016 
 
 
 
approved by the EMA in 
November 2016 
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OS data were not mature. According to protocols, 197 and 390 events would 
be needed for an OS analysis in PALOMA-3 and PALOMA-2, respectively 
[4, 21]. Palbociclib plus fulvestrant recipients showed an improvement in 
objective response, response duration, global QOL and time to deterioration 
in pain compared to placebo recipients. Uncertainty exists regarding wheth-
er the pre-specified definition for deterioration in pain ( 10 point change) 
would be considered clinically meaningful. Evidence suggests that while a 
statistically significant change may be observed using the EORTC QLQ-
C30, changes of 23.5 units and 7.2 units, are required to gain clinically im-
portant differences in pain and function, respectively [32]. By administering 
the questionnaires querying symptoms over the off-treatment week, the im-
pact of the side effects of palbociclib combination therapy on QoL may be 
attenuated. Timing of the questionnaire is critical to assessing treatment-
related outcomes. The PROs data without a prospectively specified statisti-
cal analysis plan were considered exploratory and descriptive in this study 
[29].  
The most common AEs occurring in 10% of palbociclib plus fulvestrant-
treated patients included neutropenia, leukopenia, infections, fatigue, nau-
sea, and anaemia. Grade 3 or 4 neutropenia and leukopenia were reported in 
66% and 31% of palbociclib plus fulvestrant recipients. While neutropenia 
was managed by dose modification, one death resulted from neutropenic 
sepsis. In the palbociclib combination therapy group, 54% of patients re-
quired a dose interruption due to an AE, 36% had a cycle delay, 34% had a 
dose reduction, and 6% discontinued therapy due to fatigue, infections and 
thrombocytopenia.  
While investigators suggest that primary neutropenia can be effectively 
managed by dose modification without affecting efficacy, existing studies 
suggest treatment with palbociclib is consistently punctuated by dose inter-
ruption, reduction, cycle delay or discontinuation due to AEs [3, 21]. Com-
plete blood counts are monitored at baseline and every two weeks during the 
first two cycles to identify when a dose reduction may be needed to reduce 
the effects of drug toxicity. Long-term data regarding toxicity and compli-
ance, correlated with clinically meaningful measures of QoL, will better in-
form decision makers regarding the tolerability and patient acceptability of 
palbociclib [2].  
Selective CDK4/6 inhibitors ribociclib and abemaciclib are also currently 
under development for the treatment of breast cancer [33]. Currently, palbo-
ciclib-based therapies are being studied as first- and second-line treatments 
for advanced breast cancer, as well as adjuvant and neoadjuvant therapy for 
early-stage breast cancer [34]. Palbociclib plus fulvestrant may be used fol-
lowing failure of prior ET and/or one line of chemotherapy for advanced 
disease. Physician and patient preference contribute to palbociclib’s place in 
treatment as there are no head-to-head comparisons of first-line versus sub-
sequent-line use and OS data are lacking to support PFS as a relevant end-
point [2]. 
Efficacy, cost, AEs, and patient acceptance are important factors for deci-
sions regarding clinical management and reimbursement. However, there is 
no evidence regarding the comparative OS advantage of palbociclib combi-
nation therapy with letrozole or fulvestrant or an AI alone, fulvestrant alone 
or in combination with an AI, or everolimus plus exemestane at this time 
[2]. Palbociclib costs approximately € 4,582.55 per 28-day cycle [31].  
 
PALOMA-3:  
palbociclib increased 
median PFS +4.9 
months compared to 
control 
 
data based on  
interim-analysis 
 
 
OS data incomplete 
most common AEs: 
neutropenia, 
leukopenia, infections, 
fatigue, nausea and 
anaemia 
palbociclib consistently 
punctuated by dose 
interruption, reduction, 
cycle delay or 
discontinuation due to 
AEs 
role in treatment 
regimens unclear 
lack of comparison trials  
 
 
€ 4,582.55 per 28-day 
cycle 
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Palbociclib is a first-in-class CDK4/6 inhibitor for use in combination with 
fulvestrant as treatment for HR-positive, HER2-negative advanced or MBC 
with disease progression during or following ET [3]. While palbociclib in-
creased median PFS by 4.9 months, this endpoint is not currently supported 
by OS data or clinically important differences in QoL. While Rb protein is 
the only reliable indicator for palbociclib activity until now, one may need to 
find further indicators and biomarkers to assess the efficacy of palbociclib 
for future use [34].  
first-in-class CDK4/6 
inhibitor 
 
improved PFS, but no 
OS data available 
 
additional costs and 
toxicity 
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Table 3: Benefit assessment based on ESMO-MCBS
3
 [27] and adapted benefit assessment based on ESMO-MCBS
3
 [28] 
ESMO-
MCBS 
Active 
substance 
Indication Intention PE Form 
MG 
standard  
treatment 
Efficacy Safety 
AJ FM MG 
(months) 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
adapted 
ESMO-
MCBS 
Palbociclib 
locally advanced 
or metastatic 
breast cancer 
Not  
curative PFS 2b ≤ 6 m +4.9 
0.46 
(0.36–0.59) HR ≤ 0.65 AND PFS gain ≥ 1.5 m 3 
+51% grade 
≥3 AEs (-1)4 
ND -1 2 
ESMO-
MCBS 
Palbociclib 
locally advanced 
or metastatic 
breast cancer 
Not  
curative 
PFS 2b ≤ 6 m +4.9 
0.46 
(0.36–0.59) HR ≤ 0.65 AND PFS gain ≥ 1.5 m 
3 - ND 
-1 
(AJ: d)5 
2 
Abbrevations: AJ = Adjustments, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, PE = primary endpoint, PM = preliminary magnitude of clinical benefit 
grade, QoL = quality of life  
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulted by the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours 
drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut off values and outcomes 
that lead to an up- or downgrading seem to be arbitrary. Additionally, they are independent of the primary outcome and therefore a reason for confounding. Hence, we report the adjustments 
separately. 
                                                             
3
 European Society for Medical Oncology- Magnitude of Clinical Benefit Scale 
4
 1 level downgrade, because >10% grade ≥3 adverse events. 
5
 1 level downgrade, because the drug ONLY leads to improved PFS and QOL assessment does not 
demonstrate improved QoL 
Palbociclib (Ibrance
®
) in combination with fulvestrant for the treatment of hormone-receptor-positive, 
HER2-negative advanced or metastatic breast cancer 
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Table 4: Characteristics of the phase III PALOMA-3 trial 
Title: Palbociclib (PD-0332991) combined with fulvestrant in HR-positive HER2-negative MBC after endocrine failure (PALOMA-
3) [3, 17, 18, 21] 
Study identifier NCT01942135, EudraCT 2013-002580-26 
Design PALOMA-3, an international (17 countries), MC (144 centres), DB phase III RCT designed to demon-
strate the superiority and safety of palbociclib in combination with fulvestrant (Faslodex®) over 
fulvestrant alone in prolonging PFS in women with HR-positive, HER2-negative MBC with disease 
progression following ET. Pre-/perimenopausal women received LHRH agonist therapy with goser-
lin (Zoladex® or generic).  
Duration of main phase: Enrolment: Oct 2013 to Aug 2014; interim analysis cut-off 
of Dec 2014; IDMC stopped study early in April 2015 after 
195 PFS events because efficacy was reached having 
crossed pre-specified Haybittle-Peto efficacy-stopping 
boundary ( = 0.00135) 
Duration of Run-in phase: Pre/perimenopausal women commenced LHRH agonist 4 
weeks before randomisation 
Duration of Extension phase: Latter statistical analyses at cut-off of 259 PFS events 
March 16, Median follow-up was 8.9 months. 
Hypothesis 
Exploratory (statistical analyses are after predefined stopping point): study designed to assess effi-
cacy and safety of palbociclib + fulvestrant versus fulvestrant alone. Assuming a 6 month median 
PFS for control, 238 events were needed in the treatment groups for the study to have 90% power 
to detect clinically meaningful improvement in median PFS from 6.0 to 9.38 months [HR: 0.64, 
one-sided significance =0.025]. 
Funding Sponsored by Pfizer in collaboration with AstraZeneca 
Treatment groups 
Palbociclib + fulvestrant 
(n=347) 
Palbociclib 125 mg/day orally for 3 weeks followed by 1 
week off; repeated until disease progression; dose modifi-
cation allowed in patients experiencing toxicity. 
Fulvestrant 500 mg intramuscularly on days 1, 15, 29, and 
once monthly thereafter. 
Placebo + fulvestrant 
(n=174) 
Placebo orally for 3 weeks followed by 1 week off; repeat-
ed until disease progression. 
Fulvestrant 500 mg intramuscularly on days 1, 15, 29, and 
once monthly thereafter. 
Endpoints and definitions 
 
Progression-free 
survival 
 
PFS Time from date of randomisation to radiological disease 
progression according to RECIST v1.1 assessed up to 12 
months by the investigator.  
Overall survival OS Time from date of randomisation to date of death by any 
cause assessed up to 36 months.  
Objective re-
sponse rate  
ORR 
 
OR is defined as overall CR or PR according to RECIST v1.1. 
Proportion of participants with CR or PR relative to all 
randomised participants and randomised participants with 
measurable disease at baseline, assessed up to 12 months.  
Duration of re-
sponse DOR 
Time from OR (CR or PR) to disease progression or death 
due to any cause.  
Patient reported 
outcome 
measures 
PROs 
PROs were assessed on Day 1 of cycles 1-4 and every other 
subsequent cycle starting with cycle 6 using EORTC QLQ-
C30, and its breast cancer module EORTC QLQ BR23 where 
higher scores (range 1-100) may indicate better function-
ing and QoL or worse symptom severity.  
Database lock Last verified: July 2016 
Results and Analysis  
 
Horizon Scanning in Oncology 
24 LBI-HTA | 2017 
Analysis description Primary Analysis 
Interim analysis after 195 PFS events Dec 5, 2014 resulted in stopping trial early in April 2015; 
reached pre-specified Haybittle-Peto efficacy-stopping boundary (=0.00135). 
Latter statistical analyses after 259 PFS events March 16, 2015 supported interim results.  
Efficacy analyses were intent to treat for all data up to data cut-off of March 16, 2015. 
Safety population includes patients who received at least one does of study drug. No analyses were 
done in the pre-protocol population, Patients whose treatment deviated from protocol were not 
excluded.  
For PROs, repeated measures mixed-effects analyses were performed to compare on-treatment 
overall scores and changes from baseline between groups while controlling for baseline. Between 
group, comparisons of time to deterioration in global QoL and pain were made using an un-
stratified log-rank test and Cox proportional hazards model.  
Analysis population   
Inclusion 
 Women > 18 years, of any menopausal status, with non-curable lo-
cally advanced or MBC  
 Confirmed HR-positive, HER2-negative  
 Progressed within 12 months of prior adjuvant or within 1 month 
from prior advanced/metastatic ET 
 On LHRH agonist at least 28 days, willing to switch to goserlin (Zo-
ladex®) at randomisation 
 Measurable disease defined by RECIST v1.1, or bone-only disease 
with ECOG PS0-1 
 Adequate organ and marrow function, resolved of prior therapy 
 Patient agrees to provide metastatic tumour tissue at baseline 
 
Exclusion 
 Prior treatment with fulvestrant, everolimus, or CDK or PI3K-mTOR 
inhibitor 
 Extensive advanced/metastatic, symptomatic visceral disease, or 
uncontrolled or symptomatic CNS metastases 
 Major surgery or anti-cancer therapy within 2 weeks of randomisa-
tion 
 Prior stem cell or bone marrow transplant 
 Use of potent CYP3A4 inhibitors or inducers 
 
Characteristics 
 
Palbociclib + fulves-
trant (n=347) 
Placebo + fulvestrant 
(n=174) 
Median age (range), years 57 (30–88) 56 (29–80) 
Race, n (%) 
   White 
   Asian 
   Black and others 
 
252 (73) 
74 (21) 
21 (6) 
 
133 (76) 
31 (18) 
10 (6) 
ECOG status, n (%) 
   0 
   1 
 
206 (59) 
141 (41) 
 
116 (67) 
58 (33) 
Menopausal status, n (%) 
   Premenopausal 
   Postmenopausal 
 
72 (21) 
275 (79) 
 
36 (21) 
138 (79) 
Non-measurable disease, n (%) 
   Bone 
   Others 
 
75 (22) 
4 (1) 
 
36 (21) 
0 (0) 
Measurable disease, n (%) 
   Any measurable disease 
   Visceral disease 
   Lung involvement 
   Liver involvement 
   Peritoneal involvement 
   Brain or pleural involvement 
 
268 (77) 
206 (59) 
100 (29) 
127 (37) 
2 (1) 
4 (1) 
 
138 (79) 
105 (60) 
45 (26) 
81 (47) 
1 (1) 
2 (1) 
Number of previous lines of ET, n (%) 
   1 
   2 
   ≥3 
 
160 (46) 
140 (40) 
47 (14) 
 
91 (52) 
61 (35) 
22 (13) 
Purpose of recent therapy, n (%) 
   Adjuvant therapy 
   Treatment of advanced or MBC 
 
74 (21) 
273 (79) 
 
40 (23) 
133 (76) 
Disease-free interval, n (%) 
   Data available 
   > 24 months 
   12–24 months 
   < 12 months 
 
233 (67) 
192 (82) 
30 (13) 
11 (5) 
 
123 (71) 
101 (82) 
19 (15) 
3 (2) 
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Abbreviations: AI: aromatase inhibitor; CR = complete response; DB = double blind; EORTC QLQ BR23 = European Organization for Research 
and Treatment of Cancer Breast Cancer Module; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire; EQ-5D = EuroQol-5D; ET = endocrine therapy; HER2 = human epidermal growth factor receptor 2; HR = hormone 
receptor; IDMC: independent data monitoring committee; LHRH = luteinizing hormone releasing hormone; MBC = metastatic breast cancer; MC 
= multicentre; OR = objective response ORR = overall response rate; OS = overall survival; PFS = progression-free survival; PR = partial 
response; QoL = quality of life; RECIST = Response Evaluation Criteria in Solid Tumours; RCT = randomised controlled trial 
 
Table 5: risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomized controlled trials) 
[26] 
Criteria for judging risk of bias  risk of bias 
Adequate generation of randomisation sequence: 2:1 block size of 6, via centralised interac-
tive web-based and voice-based randomisation system 
yes 
Adequate allocation concealment: via centralised interactive web-based and voice-based 
randomisation system 
yes 
Blinding 
Patient: masked to treatment group assignment, matching placebo yes 
Treating Physician: masked to treatment group assignment yes 
 
Outcome assessment: masked to treatment group assignment until IDMC 
recommended stopping at pre-planned interim analysis 
yes 
Selective outcome reporting unlikely: outcomes reported as specified in protocol yes 
No other aspects which increase the risk of bias: consistency in reporting, planned interim 
analyses that led to premature study termination; industry funded, study database held by 
industry who designed, conducted, administered treatment, collected and analysed data 
no (low) 
Risk of bias – study level low 
Abbreviations: IDMC = independent data monitoring committee 
Previous ET, n (%) 
   Sensitive to previous ET 
   AI 
   Tamoxifen 
   AI and tamoxifen 
 
274 (79) 
137 (39) 
51 (15) 
159 (46) 
 
136 (78) 
70 (40) 
23 (13) 
81 (47) 
Previous chemotherapy, n (%) 
   Neoadjuvant or adjuvant  
   Treatment of metastatic 
 
139 (40) 
113 (33) 
 
74 (43) 
64 (37) 
 Estrogen or progesterone-receptor status, n 
(%) 
   Estrogen and progesterone-receptor posi-
tive 
      ≥ median of distribution 
      < median of distribution 
   Estrogen and progesterone-receptor posi-
tive 
       ≥ median of distribution 
       < median of distribution 
 
 
 
 
81 (23) 
71 (20) 
 
 
179 (52) 
165 (48) 
 
 
 
 
40 (23) 
29 (17) 
 
 
100 (57) 
90 (52) 
Central lab median H-score (IQR); mean (SD) 
   Estrogen receptor 
   Progesterone receptor 
 
110 (40–160); 107 (74) 
10 (0–100); 53 (68) 
 
114 (23–150); 99 (72) 
20 (0–100); 51 (62) 
